Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: opalapril who wrote (8596)	2/3/1999 11:23:00 AM
From: aknahow	Respond to of 17367

I am and have always been pushing for general press releases to everyone at the same time. Biotech companies in particular appear to believe that much information of importance to shareholders must somehow be released to the scientific community first. This is what galls me. I am not sure where XOMA fits, but shareholders have yet to see any information on the partial hep. trials, the cf trial and etc. This might be because they are seeking a scientific forum first. If this is done with the results of the Meningococcemia trial it will be unfair and unbearable. I do communicate with XOMA and do ask what the accruals are for the two trials but I have always urged that XOMA report this data on a regular basis on its' web site. I try to never ask a question that would be related to "inside" information when communicating with any company. First, I don't think they will answer and second I don't ever want to have a problem with being accused of having made a trade based on inside information.

To: opalapril who wrote (8596)	2/3/1999 11:29:00 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

infobeat.com Interesting article about heart attacks and specific antibiotics. Data from the U.K. While we have heard about this before the article appears to provide more detail. Long term IMO this has implications for BPI. Would be interested in hearing why only certain antibiotics made a difference. Is this a gram negative/positive type of thing?

To: opalapril who wrote (8596)	2/3/1999 9:15:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

"One is to meet with the FDA prior to the meeting with the DSMB to get permission to continue providing Neuprex to everyone at the study sites on an open label basis" What does this mean!!!!!!!!!!!!!!!!!!!!!!!!!!!!! Or this? A second reason was that a complete halt in the trial would have put patients in the study at risk. This is clear, apparently no trick, just that it's only over when it's really over. that the end of the trial will be announced as soon as possible thereafter - no trick definitions of "end." At that point XOMA will have a rough mortality number and that after analysis she is hoping that the 95% certainly goal will be met, but, in any event, all of the data will be analyzed and that if favorable XOMA will push for expedited approval.